AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- CHM has reopened enrolment in the Phase 1B study of CHM CORE-NK plus vactosertib.
- The investigator-sponsored trial is designed to treat 12 patients with locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers.
Chimeric Therapeutics Limited (ASX: CHM) has re-opened the Phase 1B study of CHM CORE-NK plus vactosertib for enrolment. CHM CORE-NK is a universal off-the-shelf NK cell therapy which utilises the CORE-NK platform, capable of producing hundreds of doses within a single manufacturing cycle. The Phase 1B study is an investigator-sponsored study and is currently funded without financial assistance from CHM.
Previous Clinical Trial Findings on CHM CORE-NK
Previously investigated in a Phase 1 clinical trial, CHM CORE-NK demonstrated safety, with no incidence of Graft versus Host Disease (GvHD). The study showed prolonged NK cell persistence up to 28 days, and promising early indications of efficacy, especially in cases of blood cancers. In case of blood cancers, all patients achieved disease control, with one individual maintaining a complete response for over 15 months following the study's publication.
About the Phase 1B trial
Image source: Company update
The trial targets 12 patients diagnosed with either locally advanced/metastatic colorectal cancer, or those experiencing relapsed or refractory blood cancers.
CHM shares traded at AU$0.023 apiece at the time of writing on 16 May 2024.
